Welcome to our dedicated page for Marker Therapeut news (Ticker: MRKR), a resource for investors and traders seeking the latest updates and insights on Marker Therapeut stock.
Marker Therapeutics, Inc. reports developments as a clinical-stage immuno-oncology company developing non-genetically modified Multi-Antigen Recognizing T cell therapies for hematologic malignancies and solid tumor indications. Its recurring company updates center on the MAR-T cell platform, MT-601 in lymphoma, MT-401-OTS as an off-the-shelf program, and pancreatic cancer research connected to technology developed at Baylor College of Medicine.
Company news also covers clinical observations from named studies, non-dilutive funding from government and cancer-research programs, scientific publications and medical-meeting presentations, quarterly financial results, conference participation, shareholder voting matters, and board governance changes.
Marker Therapeutics, Inc. (NASDAQ: MRKR) announced that Chief Financial Officer Anthony H. Kim will present at the virtual Raymond James Human Health Innovation Conference on June 21, 2021, at 9:20 a.m. ET. Marker Therapeutics is focused on developing next-generation T cell-based immunotherapies for treating hematological malignancies and solid tumors. The presentation will be available via a live webcast on their website and can be replayed afterward. The company's innovative approach emphasizes non-engineered, tumor-specific T cells, potentially reducing manufacturing costs and toxicities while enhancing patient outcomes.
Marker Therapeutics, Inc. (Nasdaq:MRKR) reported its Q1 2021 financial results, highlighting a net loss of $8.8 million compared to $6.5 million in Q1 2020. The company closed a public offering raising approximately $56.5 million, strengthening its cash position to $64.5 million, sufficient to fund operations into Q1 2023. Significant advancements include dosing the first patient in a Phase 2 trial for AML and the operationalization of a new cGMP facility. Expected milestones include initiating the main trial phase in Q3 2021 and completing patient enrollment by Q4 2021.
Marker Therapeutics, Inc. (Nasdaq:MRKR) will host a conference call and webcast on May 12, 2021, at 5:00 p.m. ET to discuss its first quarter 2021 financial results and provide a corporate update. Participants can join via the company's website or by calling 877-407-8913 (domestic) or 201-689-8201 (international). After the event, the archived webcast will be available for replay. Marker Therapeutics specializes in developing T cell-based immunotherapies for hematological malignancies and solid tumors, claiming advantages over current engineered therapies.
Marker Therapeutics (Nasdaq:MRKR) announced the presentation of new robotics technology for manufacturing multi-tumor-associated antigen (mTAA)-specific T cell therapies at the ASGCT Annual Meeting from May 11-14, 2021. Lead author Anastasiya Smith, Ph.D., will discuss a robotic assistant prototype, co-designed with ABB Robotics, which demonstrated superior precision in liquid handling compared to human operators. This innovation aims to simplify processes and enhance the availability of cell therapies to a broader patient population, particularly for treating hematological cancers like acute myeloid leukemia (AML).
Marker Therapeutics, Inc. (Nasdaq: MRKR) has completed an underwritten public offering of 32,282,857 shares of common stock at a price of $1.75 per share, generating approximately $56.5 million in gross proceeds. The offering, managed by Piper Sandler & Co., Cantor Fitzgerald & Co., and Oppenheimer & Co. Inc., was conducted under a shelf registration statement declared effective by the SEC on June 25, 2019. The funds raised are expected to support the company’s development of T cell-based immunotherapies for hematological malignancies and solid tumors.
Marker Therapeutics, Inc. (NASDAQ:MRKR) announced that President and CEO Peter L. Hoang will present at the Virtual Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 3:10 p.m. ET. This clinical-stage immuno-oncology company focuses on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors. A live webcast of the presentation will be accessible on Marker’s website, with a replay available afterwards.
Marker Therapeutics, Inc. (Nasdaq: MRKR) has announced the pricing of an underwritten public offering of 28,572,000 shares at $1.75 each, aiming to raise approximately $50 million before expenses. A 30-day option for underwriters to purchase an additional 4,285,800 shares has been granted. The offering, managed by Piper Sandler & Co. and Cantor Fitzgerald & Co., is expected to close around March 16, 2021, subject to customary conditions. This transaction is part of a shelf registration statement effective since June 25, 2019.
Marker Therapeutics, Inc. (Nasdaq: MRKR) announced a public offering of its common stock, with underwriters receiving a 30-day option to purchase additional shares. This offering is subject to market conditions and does not guarantee completion or specify terms. Piper Sandler & Co. is the sole book-running manager. The offering follows a shelf registration statement effective since June 25, 2019. Investors can access a preliminary prospectus through the SEC's website. Forward-looking statements about the offering's timing and details are included, reflecting potential risks.
Marker Therapeutics (MRKR) provided a corporate update and financial results for FY 2020, reporting a net loss of $28.7 million, up from $21.4 million in 2019. They launched a Phase 2 trial for AML, dosing their first patient in March 2021, and activated seven clinical sites, expecting up to 20 total. Their new cGMP manufacturing facility in Houston, designed for scalability, will support AML trials and future commercialization. Marker has $21.4 million in cash, funding operations into Q1 2022, but R&D expenses rose to $18.9 million.
Marker Therapeutics, Inc. (NASDAQ:MRKR) has announced the initiation of its Phase 2 trial for MT-401, a MultiTAA-specific T cell therapy aimed at treating patients with acute myeloid leukemia (AML) post-stem cell transplant. The trial, enrolling 160 patients across 20 cancer centers, will assess the therapy's effectiveness in both adjuvant and active disease settings. The primary goal for the adjuvant group is relapse-free survival, while the active group focuses on complete response rates. Topline results for the active group are expected in Q1 2022, addressing a significant unmet need for AML patients.